Table 4.
Prescribing of SGLT-2is in type 2 diabetes; multilevel logistic regression model (clustered at the practice level)
Characteristic | OR | 95% CI | p-value |
---|---|---|---|
Age (years) | 0.98 | 0.975–0.979 | < 0.001 |
Gender | |||
Female | 1.00 [Reference] | ||
Male | 1.13 | 1.083–1.185 | < 0.001 |
Ethnicity | |||
White | 1.00 [Reference] | ||
Asian | 0.88 | 0.806–0.954 | 0.002 |
Black | 0.60 | 0.522–0.683 | < 0.001 |
Mixed | 0.66 | 0.521–0.843 | < 0.001 |
Other | 0.75 | 0.597–0.939 | 0.012 |
IMD Quintile | |||
1 (most deprived) | 0.95 | 0.871–1.044 | 0.300 |
2 | 0.99 | 0.907–1.071 | 0.737 |
3 | 1.00 | 0.922–1.079 | 0.953 |
4 | 1.01 | 0.937–1.088 | 0.795 |
5 (least deprived) | 1.00 [Reference] | ||
BMI category (kg/m2)a | |||
Underweight | 0.21 | 0.083–0.549 | 0.001 |
Normal | 1.00 [Reference] | ||
Overweight | 2.05 | 1.841–2.274 | < 0.001 |
Obese | 3.84 | 3.472–4.250 | < 0.001 |
eGFR (mL/min/1.73m2) | |||
< 45 | 0.03 | 0.011–0.080 | < 0.001 |
45–59 | 0.18 | 0.145–0.224 | < 0.001 |
≥ 60 | 1.00 [Reference] | ||
Comorbidities | |||
Heart failure | 0.81 | 0.653–0.998 | 0.048 |
CVD | 0.69 | 0.636–0.739 | < 0.001 |
Other covariates | |||
Systolic BP (mmHg) | 1.00 | 0.996–0.999 | 0.001 |
HbA1c (mmol/mol) | 1.03 | 1.029–1.031 | < 0.001 |
Diuretic | 0.74 | 0.682–0.804 | < 0.001 |
OR odds ratio, BMI body mass index, BP blood pressure, CVD cardiovascular disease, HbA1c glycated haemoglobin, IMD Index of Multiple Deprivation
aBMI categories closest to first SGLT-2- prescription: underweight, < 18.5 kg/m2; normal, 18.5–24.9 kg/m2; overweight, 25.0–29.9 kg/m2; obese, ≥ 30 kg/m2